Aamund: The shareholders will thank us for our choice of strategy
The Chairman of Bavarian Nordic says there is a great interest in the company’s prostate cancer vaccine, Prostvac, on the market.
by Benjamin Werner Christensen & Henrik Tüchsen
There is currently a “significant interest” in a collaboration concerning Bavarian Nordic’s candidate drug against prostate cancer, the vaccine prostvac, says Chairman of the board, Asger Aaamund, who is certain that the shareholders will someday thank the company’s management for the chosen strategy.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
